A. High risk – recommend prescribing daily PrEP if the patient acknowledges
Having had any of the following in the last 3 months •Being a regular sexual partner of an HIV+ person (not on treatment and/or with detectable viral load) with whom condoms have not been consistently used •At least one episode of receptive anal or vaginal condomless intercourse (CLI) with any casual HIV+ partner or a male homosexual or bisexual partner of unknown status •A female patient in a serodiscordant heterosexual relationship, who is planning natural conception in the next 3 months	AND	Being likely to have in the next 3 months (indicating sustained risk) •Multiple episodes of CLI with or without sharing intravenous drug equipment
B. Medium risk – consider prescribing daily PrEP, based on a case-by-case approach if discussion reveals
The patient acknowledges having had any of the following in the last 3 months •At least one episode of CLI with a heterosexual partner, not known to be HIV–, from a country with high HIV prevalence	AND	Being likely to have in the next 3 months (indicating sustained risk) •Multiple episodes of CLI with a heterosexual partner, not known to be HIV+, but at high risk of being HIV+ with or without sharing injecting equipment
Case-by-case approach Based on a complete sexual and alcohol and other drug-using history and the personal circumstances of the patient, if the clinician is of the opinion that the patient is likely to be at high risk of HIV, then PrEP prescription may be considered despite the absence of reported high- or medium-risk factors above. Specific consideration should be given to recommending PrEP to a patient who is travelling to one or more countries with high HIV prevalence and is likely to be sexually active while travelling.